Metastatic Lymph Node 51 (MLN51) cDNA was isolated by differential screening of a human breast cancer metastasis cDNA library. MLN51 cDNA encodes a novel human protein of 703 residues that shares no significant homology to any known protein. However MLN51 is well conserved between vertebrate and invertebrate species suggesting an important biological function. The amino terminal half of the protein contains a coiled-coil domain and two potential nuclear localization signals (NLS). The carboxy terminal half contains one SH2 and four SH3 binding motifs. The coiled-coil domain promotes MLN51 oligomerization in transfected cells. When transiently expressed, the MLN51 protein is mainly found in the cytoplasm with a weak nuclear staining. However, deletion of the carboxy terminal half of the protein allows the targeting of the protein to the nucleus, demonstrating that the NLSs are functional. MLN51 is ubiquitously expressed in normal tissues. Human breast carcinomas show MLN51 overexpression in malignant epithelial cells. The uncommon association of protein -protein interaction domains often found either in nuclear or in cytoplasmic signaling proteins raises a possible nucleo-cytoplasmic function for MLN51.
Metastatic Lymph Node 51 (MLN51) cDNA was isolated by differential screening of a human breast cancer metastasis cDNA library. MLN51 cDNA encodes a novel human protein of 703 residues that shares no significant homology to any known protein. However MLN51 is well conserved between vertebrate and invertebrate species suggesting an important biological function. The amino terminal half of the protein contains a coiled-coil domain and two potential nuclear localization signals (NLS). The carboxy terminal half contains one SH2 and four SH3 binding motifs. The coiled-coil domain promotes MLN51 oligomerization in transfected cells. When transiently expressed, the MLN51 protein is mainly found in the cytoplasm with a weak nuclear staining. However, deletion of the carboxy terminal half of the protein allows the targeting of the protein to the nucleus, demonstrating that the NLSs are functional. MLN51 is ubiquitously expressed in normal tissues. Human breast carcinomas show MLN51 overexpression in malignant epithelial cells. The uncommon association of protein -protein interaction domains often found either in nuclear or in cytoplasmic signaling proteinsIntroduction Breast cancer is a frequent form of cancer and one of the highest causes of mortality by cancer among women (Boyle et al., 2000) . The main cause of breast cancer treatment failure and death is the formation of secondary tumors (metastasis) in organs, such as lymph nodes, bone, liver and lung (Liotta, 2001) . In order to identify novel genes involved in primary tumor formation and/or progression, we performed a differential screening from a breast cancer-derived metastatic lymph node cDNA library using two subtracted probes representating malignant (metastatic lymph node, MLN) or non-malignant (fibroadenoma) breast tissue (Tomasetto et al., 1995b) . From this differential screening, four novel cDNAs were identified: MLN50/Lasp-1 (Tomasetto et al., 1995a) , MLN62/ CART1/TRAF4 (Regnier et al., 1995) , MLN64 (Moog-Lutz et al., 1997) and MLN51.
MLN51 has been mapped to the q12 -q21.3 region of the long arm of chromosome 17 (Tomasetto et al., 1995b) , a region known to contain the c-erbB-2 gene. The product of c-erbB-2 is a tyrosine kinase receptor, related to epidermal growth factor receptor (EGFR). The cerbB-2 gene is amplified and overexpressed in approximately 30% of human breast carcinomas and plays an important role in human malignancies (Yu and Hung, 2000) . In the majority of cases, c-erbB-2 overexpression correlate with tumor chemo-resistance and poor patient prognosis (Klapper et al., 2000) . Amplification is one of the most common genetic alterations found in cancers. In contrast to mutations that involve a single gene product, amplifications involve several distinct genes. Indeed, amplicons are characterized by the presence of multiple actively transcribed genes. These genes are believed to cooperate in cancer development and/or progression. The region q11 -q21 of chromosome 17 is particularly dense in genes and is frequently amplified in cancers. The gene encoding the adapter protein Growth Receptor Bound 7 (Grb7) lies close to the c-erbB-2 gene (Stein et al., 1994) . Grb7, a member of the Grb2 protein family, plays a fundamental role in tyrosine kinase signaling (Daly, 1998) . Most importantly, Stein et al (1994) have demonstrated a direct interaction between c-erbB-2 and Grb7 in breast cancer biopsies. In addition, in esophageal cancers, co-amplification and co-expression of Grb7 with EGFR or c-erbB-2 was significantly related to extratumoral invasion (Tanaka et al., 1997) . Using a partial MLN51 cDNA as probe, we have previously shown that MLN51 mRNA is overexpressed in breast cancers and breast metastasis (Tomasetto et al., 1995b) . Moreover, in breast cancers, MLN51 is co-amplified with c-erbB-2 gene (Bieche et al., 1996) .
In the present study, we have isolated the complete human MLN51 cDNA and characterized the structure of its encoded protein. Finally, the cellular and subcellular localization of the protein have been studied in breast tissues.
Results

MLN51 cDNA sequence
The initial MLN51 cDNA sequence did not contain any ATG in a good context to initiate translation and had a size of 3200 bp, inferior to the 4000 bp transcript size detected by Northern blot (Tomasetto et al., 1995b) . However the presence of a poly(A) + sequence indicated that the 3' end of the transcript was present. Therefore, to isolate the 5' end of this transcript, a random-primed cDNA library derived from human placenta was screened using a probe corresponding to the 5' end of the MLN51 established cDNA sequence. Different overlapping clones were obtained and sequenced in both orientations. The longest clone contained a cDNA fragment of approximately 1800 bp and lacked the MLN51 cDNA 3' end. Alignment of this sequence to the previously established sequence allowed the deduction of a complete MLN51 cDNA of approximately 4200 bp.
In order to verify this sequence, we performed RT -PCR to amplify the MLN51 mRNA from the SK-BR-3 and MCF7 cell lines using different sets of primers (see Materials and methods). Three overlapping fragments of 2794 bp (primers RM24/RM22), 1218 bp (primers SP179/RV70) and 482 bp (primers AAC187/SR27) covering 3845 bp of the potential MLN51 cDNA sequence (nucleotides 220 to 4065) were obtained from mRNAs of both cell lines and sequenced. Alignment of the amplified product sequences with the MLN51 cDNA sequence revealed the presence of a gap in the alignment (136 nucleotides, from 1769 to 1905). Because the complete sequence of the MLN51 gene is now available from the systemic sequencing of the human genome (Accession no. AC068669), we compared the two MLN51 cDNA sequences to the MLN51 gene sequence. Alignments showed that the sequence disagreement between the two cDNAs was caused by the presence of a partially unspliced intron that remained in the original cDNA clone.
Thus, the complete MLN51 cDNA contains 4119 bp (updated accession no. X80199; Figure 1a ), a size consistent with that of MLN51 transcript (see Figure  3a) . The first ATG codon (nucleotide position 234 -236, Figure 1a ) has a favorable context for initiation of translation (Kozak, 1987) . Translation ends at a TAA stop codon (nucleotide position 2343 -2345) leaving around 1700 bp of 3' untranslated region. A classical AATAAA poly(A) + addition signal sequence (Wahle and Keller, 1992) was located 17 bp upstream of the poly(A) + stretch ( Figure 1a) . Moreover, an in frame stop codon (Figure 1a , nucleotides 140 -142) was found in the 5' untranslated region indicating that the coding sequence was complete.
Amino acid sequence analysis of MLN51 protein
The deduced MLN51 open reading frame encodes a 703 amino acid protein (Figure 1a, b) , with a predicted molecular weight of 76 kDa and a pHi of 6.05. The MLN51 protein possesses several potential phosphorylation sites specific for cAMP-and cGMP-dependent protein kinases (KRYS, (520) (521) (522) (523) , casein kinase II (TEDE, (13) (14) (15) (16) SGSD, (21) (22) (23) (24) SAEE, (71) (72) (73) (74) SECE, (75) (76) (77) (78) SDYE, (90) (91) (92) (93) SAED, (94) (95) (96) (97) SEGE, SEEE, (106) (107) (108) (109) SKVE, (111) (112) (113) (114) STKE, (126) (127) (128) (129) TQEE, (197) (198) (199) (200) SRQE, (232) (233) (234) (235) SVRD, (358) (359) (360) (361) SGLE, (460) (461) (462) (463) SIME, (541) (542) (543) (544) THGD, (559) (560) (561) (562) , protein kinase C (SQR, (50) (51) (52) STK, (126) (127) (128) SHR, (281) (282) (283) TGR, (304) (305) (306) TVK, (342) (343) (344) (345) SYR, (348) (349) (350) SRR, (351) (352) (353) SVR, (358) (359) (360) (361) SQR, (524) (525) (526) TYK, (689) (690) (691) and tyrosine kinase (RPIEKKSY, (397) (398) (399) (400) (401) (402) (403) (404) .
A putative coiled-coil domain is present in the Nterminal part of the protein (92 -131). A coiled-coil domain is a structural motif formed between two or more amphiphatic a-helices (Lupas, 1996) .
The MLN51 protein has a high proline content (14.4% of the total amino-acid composition), especially inside the C-terminal part of the protein (22.7% from amino acids 352 -703). In this context, we looked for the presence of protein interaction domains that bind to proline-rich regions. The Src homology region 3 (SH3) domain binds to the proline-rich region containing the PXXP core motif. Two classes of SH3 binding motifs have been described according to the position of a positively charged residue in the environment of the PXXP motif. Class I and class II SH3 binding motifs correspond to the following consensus sequences +XXPXXP and PXXPX+ (where + refers to a positively charged amino acid), respectively (Kay et al., 2000) . One class I motif (RPVPEPP, 528 -534) and three class II motifs (PPPPDR, (392) (393) (394) (395) (396) (397) (398) PTPPTK, (442) (443) (444) (445) (446) (447) were found in the MLN51 protein. In addition, we noticed the presence of a potential binding site for the profilin protein (LPPPPPP, (642) (643) (644) (645) (646) (647) (648) ) that belongs to the PRM1 consensus site (Holt and Koffer, 2001 ) within the proline-rich part of the MLN51. Profilin requires a minimum of six to eight consecutive prolines for highaffinity binding and is believed to link signaling pathways to remodeling of the actin skeleton (Kay et al., 2000; Sohn and Goldshmidt-Clermont, 1994) .
The deduced primary sequence of MLN51 contains one putative tyrosine phosphorylation site (Y 404 ). It has been previously reported that Src homology region 2 (SH2) domains (Sadowski et al., 1986; Mayer et al., 1988) bind to phospho-tyrosine (Schlessinger, 1994) , and that this interaction depends on carboxy proximal amino acids. Indeed, short tri-peptides, following the phospho-tyrosine residue, are responsible for the specificity (Songyang et al., 1994) . SH2 domains are important for protein -protein interactions and provide phosphorylation-dependent and sequence-specific contacts for the assembly of receptor signaling complexes. SH2 domains were divided into four subgroups (Songyang et al., 1993) . SH2 domains that recognize phosphotyrosine (pY) in the pY-hydrophilichydrophilic-hydrophobic context are named group 1 SH2 domains. Group 2 contains only one member, the Vav SH2 domain. Group 3 SH2 domains recognize pY in the pY-hydrophobic-X-hydrophobic context. Group 4, including the Shc SH2 domain, contains additional SH2 domains for which no consensus motif has yet (SRA, (405) (406) (407) following the MLN51 putative pY residue (Y 404 ) fit with the consensus group 1 SH2 binding motifs (Songyang et al., 1993) suggesting that MLN51 could interact with SH2 group 1-containing proteins.
Conventional nuclear localization signals (NLSs) are classified into three categories. First, the monopartite NLS, resembling the SV40 large tumor antigen NLS, contains one cluster of basic residues (PKKKRKV). Second, bipartite NLSs found in retinoblastoma proteins consist of two stretches of basic residues separated by a spacer of 10 to 12 amino acids (KR(X) 10-12 KKLR). Besides monopartites and bipartites, other types of NLSs are found, such as those in Mata2 and c-myc proteins. In the yeast protein Mata2, the NLS is composed of charged/polar residues interspersed with non-polar residues, in the c-myc protein, a central basic cluster (PAAKRVKLD) is flanked on both sides by a proline and an aspartic acid residue, respectively (reviewed in Jans et al., 2000) . Two potential monopartite NLSs composed of seven amino acids (PKGRQRK, (204) (205) (206) (207) (208) (209) (210) PRRIRKP, (255) (256) (257) (258) (259) (260) (261) are present in the MLN51 protein (Figure 1a, b) .
At the nucleotide and protein levels, sequence comparison with sequences available in databases shows no homology with any known gene and protein.
In addition, expressed sequence tags (ESTs) isolated from different species including mouse, rat, pig and cow showed at the nucleotide level an average score of 90% homology to the MLN51 human sequence indicating that MLN51 is well conserved in mammals. Potential proteins deduced from the complete sequencing of C. elegans (Accession no. CAB97236) and D. melanogaster (Accession no. AE003762) genomes, share respectively 41 and 48% similarity with the human MLN51 protein, showing that MLN51 is also conserved in invertebrates.
Despite its lack of homology to known proteins, many protein consensus sites are present within the MLN51 coding sequence. Among them, several putative protein -protein binding domains were identified, the amino terminal half of the protein contains notably, a coiled-coil domain and two monopartite NLSs. The carboxy terminal half is proline-rich and contains four SH3 binding domains and one SH2 binding domain (Figure 1b ).
Abnormal electrophoretic migration of MLN51
To demonstrate that the predicted amino acid sequence was correct, two expression vectors were constructed. The first vector (pCR3.1-MLN51) contains the complete MLN51 cDNA. The second vector contains the complete MLN51 open reading frame fused with a carboxy-terminal Flag peptide sequence (pRK5-MLN51). In both cases initiation of translation is controlled by the MLN51 endogenous sequence. To further study the MLN51 protein, two antibodies raised against the amino and carboxy-terminal extremities of MLN51 protein were generated and named anti-MLN51Nt and anti-MLN51Ct, respectively. (Tomasetto et al., 1995b) , the MLN51 protein level is higher in SK-BR-3 cells compared to MCF7 cells (Figure 3a , lanes 5 and 6).
To clarify the discrepancy between the predicted and observed MLN51 protein molcular weights, we transfected COS-1 cells with a control expression vector encoding the nuclear factor kB-inducing kinase (NIK) protein fused to a carboxy-terminal Flag epitope that has a predicted molecular weight of 106 kDa and that is known to migrate at 120 kDa in conventional SDS -PAGE gels . Indeed, using an anti- Figure 2b , lane 3). The size discrepancy between the predicted and observed MLN51 molecular weights could be explained by its peculiar primary sequence. MLN51 is proline-rich, especially in its carboxy terminal half and contains many negatively charged residues in its amino terminal half (21% from amino acid 1 -351). Therefore to test the contribution of these peculiar domains in the observed electrophoretic molecular weight of the MLN51 protein, two deletion constructs containing respectively the amino-and carboxy-terminal halves of MLN51 were generated (Figure 1c Altogether, these results show that the apparent increased molecular weight of MLN51 is caused on the one hand by the presence of a charged amino terminal domain and on the other, by the carboxy terminal proline-rich domain. Indeed, proteins containing a large number of acidic residues show a retarded migration that has been attributed to the poor binding of SDS to the acidic region (Dyrks et al., 1988; Daigle and Li, 1993) and proline-rich regions can form relatively rigid structures that confer a retarded migration on conventional SDS-containing gels (Schreiber et al., 1998; Hansen et al., 1998) . 
MLN51 is a phospho-protein
By Western blot analysis, the MLN51 protein migrates as a doublet that is recognized using both MLN51 specific antibodies (Figure 2a ). This finding indicates that one or more of the potential phosphorylation sites present in the primary sequence are functional. To determine whether MLN51 is phosphorylated, protein extracts from normal (hTERT-HME1) and tumor (SK-OV-3) cells were incubated in the presence of calf intestinal phosphatase (CIP) and analysed by Western blot. As shown in Figure 2e , in treated samples, a single band was recognized using the anti-MLN51Ct antibody in both hTERT-HME1 and SK-OV-3 protein extracts, whereas in untreated samples, a doublet was detected indicating that MLN51 is a phospho-protein in normal and cancer cells.
Oligomerization of MLN51
To investigate if the coiled-coil domain of MLN51 may promote dimerization and/or oligomerization, we utilized an immunoprecipitation assay. Truncated Flag-MLN51Nt and Flag-MLN51Ct were transiently expressed in the human embryonic kidney 293 cell line, in the absence or in the presence of the untagged MLN51 full length protein (Figure 2c,d) . Flag-tagged protein complexes were precipitated with anti-Flag antibody affinity resin and eluted from the beads with an excess of the Flag peptide. Immunoblot analysis of anti-Flag immunoprecipitates using the anti-MLN51Ct antibody did not result in a detectable interaction between MLN51 and Flag-MLN51Ct (Figure 2d , lane 1). In contrast, MLN51 was co-immunoprecipitated with Flag-MLN51Nt (Figure 2d, lane 2) . In addition, we noticed that the Flag-MLN51Nt construct was able to interact with the endogenous MLN51 protein (not shown) after a long time exposure of the immunoblot. The coiled-coil domain present in the amino terminal half of the MLN51 is likely to be responsible for the oligomerization of MLN51.
MLN51 RNA and protein expression in human cell lines
We studied MLN51 expression in different breastderived cell lines (Figure 3a) . MLN51 mRNA expression is detected in all breast cancer cell lines examined including T-47D, SK-BR-3, BT-20, BT-474, MDA-MB-435, MCF7, MDA-MB-231, ZR-75-1 and HBL-100. MLN51 expression was also studied in cell lines derived from other organs (Figure 3a, lanes 10 to 21) . Low levels of MLN51 transcripts were detected in IGR 37, IMR-32, Caco-2, Hep3B, JAR, JEG-3 and A-431 while in Jurkat, HSG, HeLa and SK-OV-3 cells, derived from T cells, salivary gland, uterus and ovary, respectively, higher levels of MLN51 transcripts are detected (Figure 3a, lanes 12, 16, 17 and 18 ). Detectable levels of MLN51 transcripts were found by Northern blot analysis of RNAs extracted from normal human tissues including lymph node, skin, lung, stomach, colon and liver (data not shown). Consistent with this wide tissue distribution, ESTs corresponding to MLN51 gene were found in many tissues including bone, brain, breast, heart, kidney, liver, lung, muscle and ovary.
MLN51 protein expression was studied by Western blot analysis on protein extracts from human cell lines established from breast cancer, T cell leukemia, ovary cancer and placenta cancer. In agreement with the ubiquitious expression of the MLN51 mRNA, the MLN51 protein was detected in all cell lines with the exception of the placenta-derived cell line JAR ( Figure  3b, lane 7) .
MLN51 is ubiquitously expressed at the RNA and protein levels. Its expression is not restricted to cancer cells since normal tissues express the transcript. Besides the JAR cell line (epithelial-like cells) that does not express detectable amounts of the protein, all epithelial cell lines tested express high levels of the protein. However, MLN51 expression is not restricted to the epithelial cell lineages since Jurkat cells, derived from T lymphocytes, express high levels of the protein.
In vitro subcellular localization of MLN51
To assess the subcellular localization of the MLN51 protein, we performed indirect immunofluorescence experiments on transiently transfected MCF7 cells. A mainly cytoplasmic staining was detected when cells were transfected with the Flag-MLN51 expression vector ( Figure 4A ). A similar staining was observed using either the anti-Flag antibody ( Figure 4A, a -c) or the anti-MLN51Ct antibody ( Figure 4A, d -f) . A similar cytoplasmic staining was observed by indirect immunofluorescence experiments on cell lines expressing low (MCF-7) and high (SK-BR-3 and SK-OV-3) levels of MLN51 protein (not shown).
The nuclei of transfected cells appeared to be weakly stained. The primary sequence of MLN51 contains two potential monopartite NLSs (Figure 1b ) that are located in the amino terminal region of the protein.
To investigate whether the NLSs were functional and if the amino and carboxy regions of MLN51 contribute to its subcellular localization, the Flag-MLN51Nt containing the NLSs and the Flag-MLN51Ct containing the SH2 and SH3 binding sites were transiently expressed in MCF7 cells and processed for immunofluorescence. The subcellular distribution was revealed using an anti-Flag antibody and examined by confocal microscopy ( Figure 4B ). The complete MLN51 protein was mostly present in the cytoplasm with a faint staining of the nucleus ( Figure 4B, a -c) . FlagMLN51Nt was mainly found in the nucleus ( Figure  4B, d -f ), while the Flag-MLN51Ct protein was mostly in the cytoplasm ( Figure 4B, g -i) . In addition, transient expression of a chimeric protein containing the MLN51 NLSs (amino acids 203 to 261) fused to the carboxy-terminal end of the enhanced green fluorescent protein (EGFP) showed complete localization of the EGFP in the nucleus (not shown). Taken together, these findings show that the NLSs are functional and suggest that the carboxy terminal proline rich domain masks or inhibits the NLSs leading to the cytoplasmic localization of MLN51.
In vivo subcellular localization of MLN51
In breast cancer biopsies, MLN51 protein was detected using the anti-MLN51Ct antibody. MLN51 overexpression in cancer cells was found in 30% (15/50) cases studied. Overexpression was not associated with a specific histological type of tumor or a specific grade ( Figure 5 ). In addition, MLN51 overexpression was also observed in a liver breast cancer-derived metastasis (not shown). MLN51 was found in malignant epithelial cells of in situ and invasive carcinomas (Figure 5a) . In cancer cells the staining was intense (Figure 5b , white arrowheads), in sharp contrast to the weak staining of normal epithelial cells (Figure 5b , black arrowheads). The MLN51 protein was cytoplasmic in normal and cancer cells. However, in cancer cells the staining was uneven in the cytoplasm with often a granular appearance (Figure 5b , white arrows). We know that MLN51 can aggregate probably via its coiled-coil domain. Therefore, oligomerization can be responsible for the granular staining found in cancer cells. The fibroblasts present in the connective tissue and the endothelial cells lining blood vessels were also weakly stained for MLN51 ( Figure 5 and data not shown). All these results are in good agreement with MLN51 mRNA and protein expression observed by Northern and Western blot analysis of cell lines. MLN51 is ubiquitously expressed at low levels in normal breast cells while the protein is strongly overexpressed in the cytoplasm of cancer cells.
Discussion
The complete MLN51 cDNA was cloned, sequenced and we have characterized its product. MLN51 encodes a protein of 703 residues with no homology to any known protein. In addition, MLN51 is unique, since no homologous sequences could be detected in the human genome. However, MLN51 counterparts were found in high eukaryotes and its conservation from man to worm suggests that MLN51 has an essential biological function.
The primary sequence of MLN51 contains several putative protein -protein interaction domains. A potential coiled-coil domain is present at the amino terminal part of the protein. The coiled-coil domain, an important structure for the formation of protein dior oligomers, is found in a broad range of proteins, including skeleton proteins, motor proteins and transcription factors (Burkhard et al., 2001) . Coiled-coil domains are required to mediate essential biological functions such as interfilament polymerization (Shoeman and Traub, 1993) and transcription factor association. For instance, the transcription factor AP1 is formed by Fos and Jun dimers that occurs via coiledcoil domain interaction, this interaction is required to bind DNA and thereby modulate transcription (O'Shea et al., 1992) . From co-immunoprecipitation experiments we show that this domain is likely to be functional since MLN51 can homodimerize via its amino terminal half. This protein -protein interaction is critical for nuclear transport. By transient transfection we found that the MLN51 protein was mainly cytoplasmic with a weak nuclear staining suggesting that the NLS sequences present in MLN51 are not functional or inaccessible to the nuclear transport machinery. It has been shown that NLS sequence recognition represents a key control point in the regulation of nuclear transport. Impaired recognition of NLS can be achieved by post-translational modifications such as phosphorylation or by specific protein binding (Jans et al., 2000 and references therein) . In this context, it has been shown that the nuclear localization of the homeoprotein ESX1 is impaired by the inhibitory action of its proline-rich region, the PF/PN motif (Yan et al., 2000) . Because the carboxy terminal half of MLN51 is proline-rich we have studied the influence of this region on the subcellular localization of the protein. In transfected cells, detection of the carboxy terminal proline-rich domain of MLN51 allows the targeting of the protein to the nucleus. These results indicate that, similar to the ESX1 protein, the NLSs of MLN51 are functional, and that the proline-rich region of MLN51 inhibits the entry of MLN51 into the nucleus.
Many consensus sites for phosphorylation are present in the MLN51 primary sequence. Treatment of cell extracts with CIP showed that MLN51 is phosphorylated. However, phosphorylation is not specific to cancer cells since phosphorylated MLN51 was found in normal mammary epithelial cells. Among the consensus sites for phosphorylation, one tyrosine phosphorylation site (Y404) is present. Phosphotyrosine (pY) initiates signaling through interaction with SH2 domains. Short tri-peptides following the pY residue are responsible for the specificity of this interaction. Interestingly, the tri-peptide following the MLN51 putative pY is compatible with those already described for SH2 binding motif, suggesting that MLN51 could interact with SH2-containing proteins.
The carboxy terminal half of MLN51 is rich in proline. Among the primary structures of many ligands, the amino acid proline is critical for protein -protein interaction. Indeed, many proteinprotein interaction domains, such as SH3, WW and EVH1 (Enabled, VASP, Homology 1) domains as well as two proteins, the CD2 binding protein and Profilin, bind to proline-rich consensus sequences (Kay et al., 2000; Mayer, 2001 ). Finally, MLN51 contains one SH2, four SH3 and one Profilin potential binding sites. Most of the SH2 and SH3 domains are present in molecules involved in signaling from the surface of the cell to the nucleus. A prototype of this kind of molecule is the growth factor receptor bound (Grb) 2 protein. Grb2 binds to phosphorylated epidermal growth factor receptor (EGFR) via its SH2 domain while its SH3 domains bind to the guanine nucleotide exchange factor SOS. This interaction brings SOS to the plasma membrane into proximity with its Ras substrate and initiates its activation (Cohen et al., 1995) . Usually, SH2 and SH3 domain-binding proteins are located either at the plasma membrane or in the cytoplasm. However, recently, a family of SH3 binding proteins with a nuclear cellular localization has been described. For instance, RNA binding proteins such as Heteroribonucleoprotein K and SAM68 are found in the nucleus and associate via their SH3 binding domains to cytosolic SH3 domain containing proteins (Hobert et al., 1994; Taylor and Shalloway, 1994) . Therefore, the association of functional NLSs to SH2 and SH3 binding sites may be in the nucleus and act at both cytoplasmic and nuclear levels.
MLN51 was mapped on the q11 -q21 region of the human chromosome 17 close to the c-erbB-2 gene (Tomasetto et al., 1995b) . Amplification of this part of chromosome 17 is a frequent event in cancer and was shown to drive MLN51 mRNA overexpression (Bieche et al., 1996) . Immuno-detection of MLN51 in human breast carcinoma showed abnormally high levels of the protein in 30% of the cases studied without correlation to grade or histological type. Overexpressed MLN51 protein was localized mostly to the cytoplasm of malignant epithelial cells, while normal cells and stromal cells exhibited a low level of MLN51 expression correlating to its ubiquitous pattern of mRNA and protein expression. Alterations of its expression in cancer cells may modulate the phenotype of transformed cells.
MLN51 is a novel protein with a peculiar association of protein domains. The finding that MLN51 is an ubiquitous protein conserved from man to worm suggests that it plays an essential role in cell biology. The presence of several protein -protein interaction domains often found in signaling molecules indicates that MLN51 could be involved as an adapter protein in cell signaling. Moreover, the presence of protein domains commonly found in either nuclear or cytoplasmic protein raise the possibility that MLN51 can function as a nucleo-cytoplasmic signaling molecule.
Materials and methods
Tissue and cell cultures
Surgical specimens obtained at the Hoˆpitaux Universitaires de Strasbourg were frozen in liquid nitrogen for RNA extraction. Adjacent sections were fixed in 4% buffered formalin and paraffin embedded for histological examination.
The cell lines HEK293, HeLa, Hep3b, HSG, IGR37, Jar, Jurkat, KatoIII, MCF7, , SK-OV-3, SK-BR-3, T-47D and ZR-75-1) are described and available in the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were routinely maintained in our laboratory and cultured as recommended. The Infinity TM human mammary epithelial cell line (hTERT-HME1), a telomerase-immortalized cell line was purchased from Clontech (Palo Alto, CA, USA) and maintained as recommended by the manufacturer.
RNA preparation and analysis
Surgical specimens were homogenized in guanidinium isothiocyanate lysis buffer and purified by centrifugation through cesium chloride cushion (Chirgwin et al., 1979) . RNAs from cell lines were extracted using the single step procedure of Chomczynski and Sacchi (1987) . RNAs were fractionated by electrophoresis on 1% agarose, 2.2 M formaldehyde gels (Lehrach et al., 1977) , transferred to nylon membrane (Hybond N, Amersham Corp., Arlington Heights, IL, USA) and immobilized by baking for 2 h at 808C.
Probe preparation and hybridization
The MLN51 probe corresponding to a 1.8 kb EcoRI fragment released from MLN51 cDNA (Tomasetto et al., 1995b) was subcloned into pBluescript (Stratagen Inc., La Jolla, CA, USA). The RNA loading control GAPDH was an internal amplified fragment by RT -PCR corresponding to nucleotides 179 to 578 (Accession no. M32599).
Northern blots were hybridized at 428C in 50% formamide, 56standard saline citrate (SSC), 0.4% ficoll, 0.4% polyvinylpyrrolidine (PVP), 20 mM sodium phosphate pH 6.5, 0.5% sodium dodecyl sulphate (SDS), 10% dextran sulphate and 100 mg/ml denatured salmon sperm DNA, for 36 -48 h with 32 P-labeled probes (Feinberg and Vogelstein, 1983) diluted to 0.5 -1610 6 c.p.m./ml. Stringent washings were performed at 608C in 0.16SSC and 0.1% SDS. Blots were autoradiographed at -808C for 24 h.
cDNA library screening
From the placenta cDNA library, 100 000 plaque forming units were plated on LB agar, and the nylon filter replica (Hybond N, Amersham Corp., Arlington Heights, IL, USA) were hybridized at 428C in 50% formamide, 56SSC, 0.4% Ficoll, 0.4% PVP, 20 mmol/l sodium phosphate (pH 6.5), 0.5% SDS, 10% dextran sulphate, and 100 mg/ml denatured salmon sperm DNA for 36 -48 h with a 32 P-labeled MLN51 specific probe diluted to 1610 6 c.p.m./ml. Stringent washes were performed at 608C in 0.16SSC and 0.1% SDS. Filters were autoradiographed at -808C for 24 -72 h. Plaques that gave a signal were subjected to a secondary screening using the same conditions. Pure plaques were directly recovered as bacterial colonies using the pBluescript/l-ZAPII in vivo excision system (Stratagene, La Jolla, CA, USA).
Cloning by RT -PCR and constructs
Poly(A)
+ RNA from the breast cancer cell lines SK-BR-3 and MCF7 were subjected to first strand cDNA synthesis using oligodT or random primers and Expand Reverse transcriptase (Roche Diagnostics, Mannheim, Germany). Different MLN51 overlapping cDNA fragments were obtained by polymerase chain reaction with Expand Taq DNA polymerase (Roche Diagnostics) using the following sets of primers: 5' primer RM24 (5'-GATTAGTTACCGGT-CACGGCG-3')/reverse primer RM22 (5'-CCACAGGCTTG-AGGAGACATC-3'); 5' primer SP179 (5'-GAGGAGTCG-GAGTGTGAGAGT-3')/reverse primer RV70 (5'-CCGGAC-TTCCAATTCTGTTCTG-3') and 5' primer AAC187 (5'-GAGAGAATTCCCGTTCTCCGTAAGATGGCGGACC-3')/reverse primer SR27 (5'-GCTCTGTGCTCTCCTGTCC-GT-3'). Following amplification the PCR fragments were purified (Nucleospin, Machery Nagel, Duren, Germany) and directly subcloned into the pTadvantage vector according to the manufacturer instructions (Clontech, Palo Alto, CA, USA)
A cDNA fragment containing the complete open reading frame of MLN51 was obtained by linked PCR. First, the 5' MLN51 cDNA fragment (1 -1449) was released by an EcoRI and SmaI digest from a clone originally isolated from a human placenta cDNA library (clone 51 -8) and inserted into the pBK-CMV vector (Stratagene), thus generating the pBK-MLN51-5' plasmid. Second, the 3' MLN51 cDNA fragment (1271 -3932) was amplified by RT -PCR from SK-BR-3 mRNA using the primers described above (RM24 and RM22) and directly cloned into the pT-Advantage vector (Clontech), generating the pT-MLN51-3' plasmid. To generate a mammalian expression vector encoding MLN51 protein under its natural translation control sequences, linked PCR was performed with high fidelity polymerase (Deep Vent polymerase, New England Biolabs, Beverly, MA, USA) followed by one cycle of Taq polymerase (Sigma) using the 5' and 3' MLN51 subcloned cDNA fragments as templates and the following primers AAC187 and AAD61 (5'-GAGAGTCGACTATTCAGAAACTTGTATTAACTGGA-3'). The 2140 bp long cDNA fragment was directly subcloned into pCR3.1 expression vector (Clontech), thus generating the pCR3.1-MLN51 construct. The sequence was verified on both strands. An expression vector encoding the MLN51 protein fused to a Flag epitope at its carboxy terminal end was obtained by linking PCR using the amplified 5' and 3' MLN51 cDNA fragments described above and the following primers AAC187 and AAD59 (5'-GAGAGAATTCTGGAA-CCCTGCTTACAACCTC-3') including the 5' and 3' EcoRI restriction sites. The amplified cDNA fragment was directly subcloned into pTAdvantage plasmid thus generating pT-MLN51-EcoRI, and sequenced. The modified MLN51 cDNA fragment (2110 bp) was released by EcoRI digestion and inserted in-frame in front of the Flag epitope cDNA sequence in the pRK5 vector (BD Pharmingen, San Diego, CA, USA) thus generating pRK5-MLN51. Vectors allowing the expressing of amino-and carboxy-deleted MLN51 constructs fused with the Flag epitope were also generated. The FlagMLN51Nt expression vector that encodes amino acids 1 to 351 of the MLN51 protein fused to an amino terminal Flag epitope was obtained by PCR amplification using the pCR3.1-MLN51 plasmid as template and primers incorporating a 5' in-frame Flag cDNA sequence in a good context for initiation of translation and a 3' in-frame stop codon at position 351, (ACG 253-5'-GCCGCCATGGACTACAAG-GACGACGATGACAAGCTTATGGCGGACCGGCGGC-GGCAG-3'; ACG 254-5'-CTACTATGACCGGTAACTAA-TCTCATGC-3'). In the same manner, the Flag-MLN51Ct expression vector that encodes amino acides 352 to 703 of the MLN51 protein fused to an amino terminal Flag epitope was obtained using ACG 255 (5'-GCCGCCATGGACTACAAG-GACGACGATGACAAGCGGCGCCTAGAGACTTCTG-TGAGG-3') and AAD61. Both cDNA fragments were cloned into the pCR3.1 vector thus generating the pCR3.1-FlagMLN5Nt and pCR3.1-Flag-MLN51Ct plasmids. The sequences were verified on both strands. The pRK5-NIK vector encodes a Flag-NIK construct .
Antibodies
To generate the anti-MLN51Nt and anti-MLN51Ct rabbit polyclonal antibodies, the synthetic peptides MADQRRRQ-RASQDTEDEESC (corresponding to residues 1 -19) and CQPVTIKPPPPEVVRSRGSS (corresponding to residues 686 -703) of the MLN51 protein sequence, respectively, were coupled to ovalbumin through an additional cysteine residue and injected into New Zealand rabbits. Immunoreactive sera were affinity-purified against the synthetic peptide coupled to Sulfolink coupling gel (Pierce, Rockford, IL, USA) using conditions described by the manufacturer. The anti-actin polyclonal antibody C-11 and the anti-Flag monoclonal antibody M2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and Sigma (St. Louis, MO, USA), respectively. Cy3-conjugated affinity-purified goat anti-rabbit IgG was purchased from Jackson ImmunoResearch (West Grove, PA, USA).
Immunoprecipitation and immunoblotting
For the co-precipitation of transfected proteins, HEK293 cells (2610 6 ) were plated on 10 cm dishes and transfected with a total of 3 mg of DNA containing various expression plasmids. After 24 h, cells were washed twice in serum-free medium and incubated for 24 h in complete medium. Cells were collected and washed in phosphatebuffered saline (PBS 16) and lysed by freeze-thaw in 1 ml of lysis buffer (50 mM Tris.HCl, pH 7.5; 140 mM NaCl; 1 mM EDTA; 1% Triton X-100; protease inhibitor cocktail 16). Cellular debris were removed by centrifugation at 10 000 g for 10 min. Aliquotes of cell lysates (100 ml) were incubated for 10 -12 h at 48C with 40 ml of anti-Flag M2 monoclonal antibody affinity resin (Sigma). The beads were washed extensively with lysis buffer and bound-proteins were eluted by incubation with the Flag peptide (150 ng/ml). Eluted proteins were recovered by centrifugation. Cell extracts or eluted proteins were resolved by 8% SDS -PAGE and electrotransferred to nitrocellulose sheets (Schleicher and Schuell, Dassel, Germany). The membrane was blocked in PBS containing 3% nonfat dry milk and 0.1% Tween 20. Rabbit anti-MLN51Nt, anti-MLN51Ct and anti-Lasp-1 polyclonal sera, goat anti-actin polyclonal serum and mouse anti-Flag monoclonal serum were used as primary antibodies at dilutions of 1:1000, 1:700, 1:10 000, 1:2000 and 1:10 000, respectively. After washing, the blots were incubated with appropriate secondary antibodies. Horseradish peroxidaseconjugated AffiniPure donkey anti-rabbit or goat anti-mouse (Jackson ImmunoResearch 1:10 000) and HRP donkey antigoat (Santa Cruz Biotechnology, 1:1000) were used. Finally, protein -antibody complexes were visualized by an enhanced chemiluminescence detection system (SuperSignal West Pico, Pierce, Rockford, IL, USA). For calf intestinal phosphatase (CIP) treatment, 15 mg of the whole cell protein extracts were incubated in the presence of 1 ml of protease inhibitor cocktail (Sigma) for 1 h at 378C with five units of CIP (Promega). Similar control protein extracts were incubated in the same conditions without CIP. CIP-treated and control protein extracts were analysed by Western blotting.
Immunohistochemistry and immunocytochemistry
Immunohistochemical anslysis of breast carcinomas was performed as described, with paraffin-embedded tissue sections (Regnier et al., 1995) . After anti-MLN51Ct polyclonal antibody incubation, a peroxidase-anti-peroxidase system (DAKO, Carpinteria, CA, USA) was used for revelation.
COS-1 or MCF7 cells were transiently transfected by calcium phosphate co-precipitation (Chen and Okayama, 1987) with 3 mg of various expression vectors and grown 24 h on glass coverslips. After washing with PBS, cells were fixed 10 min at room temperature in 4% paraformaldehyde in PBS and permeabilized for 10 min with 0.1% Triton X-100 in PBS. After blocking in 1% bovine serum albumin in PBS, cells were incubated at room temperature with the primary antibodies anti-MLN51Nt, anti-MLN51Ct or anti-FlagM2 antibodies. Cells were washed three times in PBS and incubated 1 h with Cy3-conjugated appropriate secondary antibody (1:400). Cells were washed three times in PBS and nuclei were counterstained with Hoescht-33258 dye. Slides were mounted in Aqua PolyMount (Polysciences Inc., Warrington, PA, USA). Observations were made with a fluorescence microscope (Leica DMLB 30T, Leica Microsystem, Wetzlar, Germany).
Sequence analysis
Sequence analyses were performed using the GCG sequence analysis package (Wisconsin package version 8.0, Genetics Computer Group, Madison, WI, USA). Translation of the nucleotide sequence into protein was performed with the Publish program. The SH2, SH3 and profilin consensus binding sequences were identified by the Findpatterns program.
Research for MLN51 cDNA and protein sequence homologies was performed using different BLAST program (Altschul et al., 1997) against all the available databases (http://www.ncbi.nlm.nih.gov/BLAST). We used different programs on the Expasy Molecular Biology Server (http:// www.expasy.ch/tools/) to analyse the MLN51 protein sequence. The Protparam tool program was used to obtain the molecular weight and the pHi of the protein. The Profilescan program searches a single protein sequence against currently available profile databases. We used the Prosite pattern library (Bairoch et al., 1996) to identify the different potential sites of MLN51 protein post-translational modifications. PSORT and PSORTII (Nakai and Horton, 1999) , computer programs for the prediction of protein localization sites in cells, were used to determine the potential subcellular localization of the protein by searching specific localization signals. The program Coils (Lupas et al., 1991) was used to define the coiled-coil domain.
